Effects of psilocybin versus escitalopram on rumination and thought suppression in depression
Tommaso Barba, Sarah Buehler, Hannes Kettner, Caterina Radu, Bruna Giribaldi Cunha, Leor Roseman, David Nutt, David Erritzøe, Robin Carhart‐Harris
BJPsych Open September 1, 2022 DOI: 10.1192/bjo.2022.565 via OpenAlex
Summary
AI-generated from the abstractPsilocybin, but not the antidepressant escitalopram, reduced rumination and thought suppression in people with major depressive disorder six weeks after treatment. In a randomized trial of 59 participants, only those given psilocybin showed significant decreases in both maladaptive coping strategies. Among treatment responders, thought suppression decreased exclusively in psilocybin responders, while rumination decreased in both psilocybin and escitalopram responders. Reductions in rumination and thought suppression correlated with ego dissolution and psychological insight during psilocybin sessions, suggesting distinct therapeutic mechanisms for the two treatments.
Study at a glance
| Characteristics | Randomized clinical trial Peer reviewed |
|---|---|
| Sample size | 59 |
| Population | Adults with major depressive disorder |
| Interventions | Psilocybin (COMP360) Escitalopram |
| Duration | 1 week before to 6 weeks after treatment inception |
| Topics | Psilocybin |
| Keywords | Escitalopram Rumination Clinical psychology Psychiatry |
| Citations | 57 |
| Key finding | Psilocybin, but not escitalopram, significantly reduced rumination and thought suppression six weeks after treatment, with thought suppression decreases exclusive to psilocybin responders. |
Abstract
Background Major depressive disorder is often associated with maladaptive coping strategies, including rumination and thought suppression. Aims To assess the comparative effect of the selective serotonin reuptake inhibitor escitalopram, and the serotonergic psychedelic psilocybin (COMP360), on rumination and thought suppression in major depressive disorder. Method Based on data derived from a randomised clinical trial ( N = 59), we performed exploratory analyses on the impact of escitalopram versus psilocybin (i.e. condition) on rumination and thought suppression from 1 week before to 6 weeks after treatment inception (i.e. time), using mixed analysis of variance. Condition responder versus non-responder subgroup analyses were also done, using the standard definition of ≥50% symptom reduction. Results A time×condition interaction was found for rumination (F(1, 56) = 4.58, P = 0.037) and thought suppression (F(1,57) = 5.88, P = 0.019), with post hoc tests revealing significant decreases exclusively in the psilocybin condition. When analysing via response, a significant time×condition×response interaction for thought suppression (F(1,54) = 8.42, P = 0.005) and a significant time×response interaction for rumination (F(1,54) = 23.50, P < 0.001) were evident. Follow-up tests revealed that decreased thought suppression was exclusive to psilocybin responders, whereas rumination decreased in both responder groups. In the psilocybin arm, decreases in rumination and thought suppression correlated with ego dissolution and session-linked psychological insight. Conclusions These data provide further evidence on the therapeutic mechanisms of psilocybin and escitalopram in the treatment of depression.